Skip to main content
. Author manuscript; available in PMC: 2021 Mar 25.
Published in final edited form as: Clin Oncol Case Rep. 2020 Sep 17;3(5):142.

Figure 3:

Figure 3:

Cytokine levels pre- and post-CPI therapy for case patient with ulcerative colitis (UC hx) and two control (CTRL) patients without underlying colitis or other autoimmune diseases. CTRL 1 is a 39-year-old male with metastatic melanoma to the parotid gland and lymph nodes on nivolumab (pre-and post-treatment samples are 4 weeks apart, 1 cycle of nivolumab) and CTRL 2 is a 36-year-old male with metastatic melanoma to lymph nodes on nivolumab (pre-and post-treatment samples are 4 weeks apart, 1 cycle of nivolumab). The pre-treatment sample for the UC case was 25 days after colectomy. Pre-and post-treatment samples for the UC case patient are 4 weeks apart (2 cycles of nivolumab). None had significant complications at the time of the post-treatment collection. Data represent average of replicate analytes.